Sigma Planning Corp Buys New Shares in Travere Therapeutics, Inc. $TVTX

Sigma Planning Corp purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 35,090 shares of the company’s stock, valued at approximately $2,066,000.

Several other institutional investors also recently bought and sold shares of TVTX. Jupiter Topco LLC purchased a new position in shares of Travere Therapeutics during the 2nd quarter worth $643,299,000. Bank of America Corp DE purchased a new stake in shares of Travere Therapeutics in the second quarter valued at $259,527,000. Stephens Investment Management Group LLC grew its position in shares of Travere Therapeutics by 4.5% in the first quarter. Stephens Investment Management Group LLC now owns 1,798,466 shares of the company’s stock valued at $53,432,000 after purchasing an additional 76,843 shares during the period. Wellington Management Group LLP grew its position in shares of Travere Therapeutics by 50.0% in the second quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company’s stock valued at $87,094,000 after purchasing an additional 510,808 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in Travere Therapeutics by 168.1% in the third quarter. Assenagon Asset Management S.A. now owns 1,145,414 shares of the company’s stock valued at $67,442,000 after purchasing an additional 718,109 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Piper Sandler reiterated an “overweight” rating on shares of Travere Therapeutics in a research report on Monday, August 17th. Citigroup raised their price target on Travere Therapeutics from $70.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Wedbush restated an “outperform” rating and issued a $76.00 price target on shares of Travere Therapeutics in a report on Tuesday, September 22nd. HC Wainwright reaffirmed a “buy” rating and set a $67.00 price objective on shares of Travere Therapeutics in a research note on Tuesday, September 22nd. Finally, Zacks Research downgraded shares of Travere Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $69.50.

Insider Transactions at Travere Therapeutics

In related news, CEO Eric Dube sold 243,735 shares of Travere Therapeutics stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $53.82, for a total value of $13,117,817.70. Following the transaction, the chief executive officer owned 432,886 shares in the company, valued at approximately $23,297,924.52. This trade represents a 36.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Cline sold 50,508 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total value of $3,148,668.72. Following the sale, the chief financial officer directly owned 87,508 shares of the company’s stock, valued at approximately $5,455,248.72. This trade represents a 36.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,294,029 shares of company stock valued at $79,454,261 in the last ninety days. Company insiders own 4.44% of the company’s stock.

Travere Therapeutics Stock Up 1.8%

NASDAQ:TVTX opened at $50.88 on Wednesday. The firm’s 50 day moving average is $59.91 and its two-hundred day moving average is $46.22. Travere Therapeutics, Inc. has a fifty-two week low of $22.59 and a fifty-two week high of $68.73.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.03. The company had revenue of $169.58 million for the quarter, compared to analysts’ expectations of $157.27 million. The firm’s quarterly revenue was up 48.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.13 earnings per share. On average, analysts forecast that Travere Therapeutics, Inc. will post -0.92 EPS for the current year.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.